{"id":66649,"date":"2025-04-14T12:02:08","date_gmt":"2025-04-14T12:02:08","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/04\/14\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/"},"modified":"2025-04-14T12:02:08","modified_gmt":"2025-04-14T12:02:08","slug":"nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/","title":{"rendered":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition"},"content":{"rendered":"
\n

SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th<\/sup> China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025.<\/p>\n

BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique opportunity for intensive networking, collaboration, and the exploration of promising new partnerships. Covering a broad range of life science research and applications, BIOTEC-CHINA 2025 will spotlight key innovation areas such as drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.<\/p>\n\n\n\n\n\n\n\n\n\n
NKGen Presentation Details<\/u><\/strong>:<\/strong><\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
Title<\/strong>:<\/td>\nUse of Autologous Enhanced Natural Killer Cells for Alzheimer\u2019s and Parkinson\u2019s Disease<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Location:<\/strong><\/td>\nShuijing Hall, Beijing Huanghe Jingdu Conference Center, The Third Building<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Date and Time:<\/strong><\/td>\nApril 17, 2025, at 10:20 am \u2013 10:40 am CST (China Standard Time) UTC\/GMT +8<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Dr. Song will present on the use of troculeucel in the treatment of patients with Alzheimer\u2019s and Parkinson\u2019s disease, highlighting the promising results previously observed in our Phase 1 clinical trials and compassionate use cases. Additionally, Dr. Song will provide an update on NKGen\u2019s ongoing Phase 1\/2a clinical trial for moderate Alzheimer\u2019s disease, with recent data presented at the AD\/PD™ 2025 conference. The favorable clinical outcomes and biomarker data disclosed to date offer strong indications that troculeucel may emerge as a viable treatment option for patients with Alzheimer\u2019s and Parkinson\u2019s disease.<\/p>\n

Previously disclosed data for troculeucel in Alzheimer\u2019s disease can be found on the Scientific Publications page of the Company\u2019s website at https:\/\/nkgenbiotech.com\/scientific-publications\/<\/a>. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company\u2019s website at https:\/\/nkgenbiotech.com\/news\/<\/a>.<\/p>\n

About Troculeucel<\/strong>
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (\u201cINN\u201d) for SNK01 assigned by the World Health Organization (\u201cWHO\u201d). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen\u2019s journey toward bringing this therapy to market.<\/p>\n

About NKGen Biotech<\/strong>
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit\u00a0www.nkgenbiotech.com<\/a>.<\/p>\n

Forward-Looking Statements\u00a0<\/strong>
Statements contained in this press release may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201ccould\u201d, \u201ccontinue\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201coutlook\u201d, \u201cfuture\u201d and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company\u2019s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company\u2019s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company\u2019s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company\u2019s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen\u2019s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption \u201cRisk Factors\u201d and elsewhere in the Company\u2019s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission\u2019s website at www.sec.gov and on the Company\u2019s website under the subheading \u201cInvestors\u2014Financial and Filings\u201d. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

Internal Contact:<\/strong>
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com<\/a><\/p>\n

External Contact:<\/strong>
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com<\/a><\/p>\n

\"\"<\/div>\n","protected":false},"excerpt":{"rendered":"

SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking […]\n","protected":false},"author":1,"featured_media":66650,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-66649","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\nNKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition\" \/>\n<meta property=\"og:description\" content=\"SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotec\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T12:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/04\/NKGen-Biotech-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition\",\"datePublished\":\"2025-04-14T12:02:08+00:00\",\"dateModified\":\"2025-04-14T12:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\"},\"wordCount\":921,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\",\"name\":\"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-04-14T12:02:08+00:00\",\"dateModified\":\"2025-04-14T12:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/","og_locale":"en_US","og_type":"article","og_title":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition","og_description":"SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (\u201cNKGen\u201d or the \u201cCompany\u201d), a clinical-stage biotec","og_url":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-04-14T12:02:08+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/04\/NKGen-Biotech-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition","datePublished":"2025-04-14T12:02:08+00:00","dateModified":"2025-04-14T12:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/"},"wordCount":921,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/","url":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/","name":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-04-14T12:02:08+00:00","dateModified":"2025-04-14T12:02:08+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/nkgen-biotech-to-present-on-the-use-of-troculeucel-for-alzheimers-and-parkinsons-disease-at-the-7th-china-international-biotechnology-conference-exhibition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"NKGen Biotech To Present on the Use of Troculeucel for Alzheimer\u2019s and Parkinson\u2019s Disease at the 7th China International Biotechnology Conference & Exhibition"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=66649"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/66650"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=66649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=66649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=66649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}